Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07205289Phase 1Recruiting

Serum Collection Study for Assay Development

Role: lead

NCT06562790Phase 1Completed

Study of Gamma PN3 in the Elderly

Role: lead

NCT05982314Phase 1Completed

Extension Safety and Immunogenicity Study of GPNV-001

Role: lead

NCT05667740Phase 1Completed

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Role: lead

All 4 trials loaded